FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086594920> ?p ?o ?g. }

• W2086594920 endingPage "611" @default.
• W2086594920 startingPage "609" @default.
• W2086594920 abstract "The metabolic syndrome is strongly associated with insulin resistance and consists of a constellation of factors such as hypertension and hyperlipidemia that raise the risk for cardiovascular diseases and diabetes mellitus. There is a growing body of evidence to show that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, statins, reduce cardiovascular-related morbidity and mortality in patients with or without coronary artery disease. Recent clinical observations argue for a simple strategy of considering routine statin therapy for patients with type 2 diabetes. Furthermore, statin therapy is also found to be effective in allowing LDL-cholesterol goal achievement in hypercholesterolemic high-risk patients with the metabolic syndrome. However, the effects of statins on the pathogenesis of the metabolic syndrome remain to be elucidated. Several types of statins are commercially available now. Among them, pravastatin is unique because it is the only statin that has been shown to have protective role against the development of diabetes in a large clinical trial. Moreover, a recent clinical study revealed that pravastatin treatment improved insulin sensitivity in 25 women with the metabolic syndrome with impaired glucose intolerance. These observations let us to speculate that pravastatin is a promising strategy for the treatment of hypercholesterolemic patients with the metabolic syndrome. It may improve the insulin sensitivity in these patients and subsequently prevent the development of type 2 diabetes. In this paper, we would like to propose the possible ways of testing our hypothesis as follows. (1) Does pravastatin treatment improve insulin resistance in patients of the metabolic syndrome or in insulin resistant hypertensive or obese patients? If the answers are yes, are these beneficial effects of pravastatin superior to those of other anti-hyperlipidemic statins with equihypolipidemic properties? (2) Does pravastatin treatment actually reduce the development of diabetes in these insulin resistant patients? At that time, does pravastatin treatment increase serum levels of adiponectin, a key adipokine with insulin-sensitizing property? How about the effects of pravastatin treatment on adipokines that could elicit insulin resistance such as tumor necrosis factor-alpha? These clinical studies will provide further information whether pravastatin treatment can improve insulin resistance and subsequently reduce the development of diabetes in insulin resistant patients with the metabolic syndrome." @default.
• W2086594920 created "2016-06-24" @default.
• W2086594920 creator A5015715722 @default.
• W2086594920 creator A5030113532 @default.
• W2086594920 creator A5040778303 @default.
• W2086594920 creator A5086054133 @default.
• W2086594920 date "2006-01-01" @default.
• W2086594920 modified "2023-10-11" @default.
• W2086594920 title "Protective role of pravastatin in the pathogenesis of the metabolic syndrome" @default.
• W2086594920 cites W1502524639 @default.
• W2086594920 cites W1967789083 @default.
• W2086594920 cites W1996414762 @default.
• W2086594920 cites W2005615150 @default.
• W2086594920 cites W2015219110 @default.
• W2086594920 cites W2041348231 @default.
• W2086594920 cites W2045986346 @default.
• W2086594920 cites W2055657509 @default.
• W2086594920 cites W2057042511 @default.
• W2086594920 cites W2107295258 @default.
• W2086594920 cites W2121200936 @default.
• W2086594920 cites W2155598961 @default.
• W2086594920 cites W2156984585 @default.
• W2086594920 cites W424467158 @default.
• W2086594920 doi "https://doi.org/10.1016/j.mehy.2005.08.004" @default.
• W2086594920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16171951" @default.
• W2086594920 hasPublicationYear "2006" @default.
• W2086594920 type Work @default.
• W2086594920 sameAs 2086594920 @default.
• W2086594920 citedByCount "5" @default.
• W2086594920 countsByYear W20865949202021 @default.
• W2086594920 crossrefType "journal-article" @default.
• W2086594920 hasAuthorship W2086594920A5015715722 @default.
• W2086594920 hasAuthorship W2086594920A5030113532 @default.
• W2086594920 hasAuthorship W2086594920A5040778303 @default.
• W2086594920 hasAuthorship W2086594920A5086054133 @default.
• W2086594920 hasConcept C126322002 @default.
• W2086594920 hasConcept C134018914 @default.
• W2086594920 hasConcept C2776839432 @default.
• W2086594920 hasConcept C2777180221 @default.
• W2086594920 hasConcept C2777391703 @default.
• W2086594920 hasConcept C2778163477 @default.
• W2086594920 hasConcept C2778213512 @default.
• W2086594920 hasConcept C2779091943 @default.
• W2086594920 hasConcept C2779134260 @default.
• W2086594920 hasConcept C2779519902 @default.
• W2086594920 hasConcept C2780578515 @default.
• W2086594920 hasConcept C2780942790 @default.
• W2086594920 hasConcept C2910068830 @default.
• W2086594920 hasConcept C555293320 @default.
• W2086594920 hasConcept C60644358 @default.
• W2086594920 hasConcept C71924100 @default.
• W2086594920 hasConcept C86803240 @default.
• W2086594920 hasConceptScore W2086594920C126322002 @default.
• W2086594920 hasConceptScore W2086594920C134018914 @default.
• W2086594920 hasConceptScore W2086594920C2776839432 @default.
• W2086594920 hasConceptScore W2086594920C2777180221 @default.
• W2086594920 hasConceptScore W2086594920C2777391703 @default.
• W2086594920 hasConceptScore W2086594920C2778163477 @default.
• W2086594920 hasConceptScore W2086594920C2778213512 @default.
• W2086594920 hasConceptScore W2086594920C2779091943 @default.
• W2086594920 hasConceptScore W2086594920C2779134260 @default.
• W2086594920 hasConceptScore W2086594920C2779519902 @default.
• W2086594920 hasConceptScore W2086594920C2780578515 @default.
• W2086594920 hasConceptScore W2086594920C2780942790 @default.
• W2086594920 hasConceptScore W2086594920C2910068830 @default.
• W2086594920 hasConceptScore W2086594920C555293320 @default.
• W2086594920 hasConceptScore W2086594920C60644358 @default.
• W2086594920 hasConceptScore W2086594920C71924100 @default.
• W2086594920 hasConceptScore W2086594920C86803240 @default.
• W2086594920 hasFunder F4320320912 @default.
• W2086594920 hasIssue "3" @default.
• W2086594920 hasLocation W20865949201 @default.
• W2086594920 hasLocation W20865949202 @default.
• W2086594920 hasOpenAccess W2086594920 @default.
• W2086594920 hasPrimaryLocation W20865949201 @default.
• W2086594920 hasRelatedWork W1530920220 @default.
• W2086594920 hasRelatedWork W2011167996 @default.
• W2086594920 hasRelatedWork W2348185047 @default.
• W2086594920 hasRelatedWork W2349677418 @default.
• W2086594920 hasRelatedWork W2367156482 @default.
• W2086594920 hasRelatedWork W2372513369 @default.
• W2086594920 hasRelatedWork W2388388456 @default.
• W2086594920 hasRelatedWork W2418222291 @default.
• W2086594920 hasRelatedWork W3029746503 @default.
• W2086594920 hasRelatedWork W4214654159 @default.
• W2086594920 hasVolume "66" @default.
• W2086594920 isParatext "false" @default.
• W2086594920 isRetracted "false" @default.
• W2086594920 magId "2086594920" @default.
• W2086594920 workType "article" @default.